Page 14 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers

New Therapies for Advanced Bladder Cancer

1
st
1 Line Immunotherapy Pembrolizumab , Locally advanced or metastatic UC who are not eligible for cisplatin-
atezolizumab 2 containing chemotherapy and whose tumours express PD-L1 [CPS ≥10]
Health Canada approved as determined by a validated test,
OR ineligible for any platinum-containing chemotherapy regardless of
PD-L1 status
Chemo-Immunotherapy Atezolizumab 5 Untreated locally advanced or metastatic UC in both platinum-eligible
and platinum-ineligible patients

1
2 nd Line Immunotherapy Pembrolizumab , Disease progression or recurrence following platinum chemotherapy for
2
atezolizumab , locally advanced or metastatic disease
Health Canada approved avelumab ,
3
durvalumab 4
FGFR inhibitor Erdafitinib 5 Disease progression or recurrence following prior chemotherapy for
locally advanced or metastatic disease, whose tumours have FGFR
Health Canada approved gene alterations

3 Line Antibody-drug Enfortumab vedotin Disease progression or recurrence following platinum chemotherapy
rd
conjugate and immunotherapy for locally advanced or metastatic disease,
OR ineligible for cisplatin therapy, and progression/recurrence following
checkpoint inhibitor therapy
UC, urothelial carcinoma; CPS, combined positive score
1. Merck Canada. Product Monograph: Keytruda. Merck Sharp & Dohme Inc; 2019; 2. Hoffman-La Roche Limited. Product Monograph: Tecentriq. Hoffman-La Roche Limited; 2019; 3. EMD Serono.
Product Monograph: Bavencio. EMD Inc; 2019; 4. AstraZeneca Canada Inc. Product Monograph: Imfinzi. AstraZeneca CAnada Inc; 2019; 5. Janssen Inc. Product Monograph: Balversa. Janssen
Canada Inc; 2019; 5. Grande E et al. 2019 ESMO; Abstract LBA14_PR.